Supplementary Material. STK1p as a prognostic biomarker for overall
survival in non-small cell lung carcinoma, based on real-world-data.
Although the patients of early stages (I-IIIA)
showed a good prognosis with high OS rates (Table 1, figure 1B), it was noted
that 3 patients of stage IIA-IIB died within 14-20 months after end of the
treatment. We observed that the STK1p values after 2-cycle
individual-chemotherapy did not returned to normal values (<0.6 pM),
characterized as NR (no response, SD) by CT examination. The main reason for
the death might be development of metastasis. Here we report a case analysis of
these three patients to prove the significant correlations between STK1p values
and clinical data in this RWD study.
This project was supported by the Major Special Funds of National Science and Technology in China: “Innovate New Drugs for the Prevention of Major Diseases and Establish Demonstrative Technology Platform for International Standardized Clinical Evaluation（2018ZX09201-013）and Science and Technology Projects of JiangSu city (SS201631). Ji Zhou is the owner of Sino Swed Tongkang Bio Tech Inc., Shenzhen, China, which produces the STK1p kit. The authors acknowledge support from the Affiliated Hospital of Suzhou University, JiangSu, China, the Peking 301 General Hospital, China, and the Medicine Department, Shenzhen Precision Medicine Institute, Shenzhen, China.